BioCentury
ARTICLE | Clinical News

Iluvien regulatory update

December 10, 2012 8:00 AM UTC

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against the use of Iluvien fluocinolone acetonide intravitreal implant from Alimera to treat chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Alimera said it is developing a patient access scheme (PAS) to address the committee's cost concerns. Despite Alimera's submission of an updated economic model, the committee concluded the most plausible incremental cost-effectiveness ratio (ICER) for Iluvien would be at least £47,600 ($76,384), well above the company's estimate of £19,300 ($30,971). ...